PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-26

Study Completion Date

2026-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase 1/2a study will explore the safety and efficacy of PTT-936, an Alpha Kinase 1 (ALPK1) activator, used alone or in combination with anti-PD-1/L1 therapy in patients with locally advanced or metastatic solid tumors. The study is divided into two parts: Phase 1 (Part A) focuses on determining the pharmaceutically active dosage range and evaluating the safety profile of PTT-936 when administered as a monotherapy. Phase 2a (Part B) will assess the safety and efficacy of PTT-936 combined with anti-PD-1/L1 therapy in patients suitable for anti- PD-1/L1 monotherapy. The study aims to understand how PTT-936, alone or in combination, impacts tumor progression and patients' overall response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients

NCT07171606

First-line Advanced NSCLC Patients

RECRUITING PHASE2

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

NCT05693844

Advanced or Metastatic Solid Tumors

RECRUITING PHASE1/PHASE2

Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors

NCT05579275

Malignant Solid Tumors

RECRUITING EARLY_PHASE1

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

NCT04989322

Nsclc EGFR Activating Mutation EGF-R Positive Non-Small Cell Lung Cancer +3 more

UNKNOWN PHASE2

Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC

NCT03987867

Non-small Cell Lung Cancer First-line Treatment

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Locally Advanced or Metastatic Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PTT-936 Dose Level 1

PTT-936 will be administered once a week (QW)

Group Type EXPERIMENTAL

PTT-936

Intervention Type DRUG

Eligible patients will receive single-agent PTT-936 administered per orally (PO).

PTT-936 Dose Level 2

PTT-936 will be administered once a week (QW)

Group Type EXPERIMENTAL

PTT-936

Intervention Type DRUG

Eligible patients will receive single-agent PTT-936 administered per orally (PO).

PTT-936 Dose Level 3

PTT-936 will be administered once a week (QW)

Group Type EXPERIMENTAL

PTT-936

Intervention Type DRUG

Eligible patients will receive single-agent PTT-936 administered per orally (PO).

PTT-936 Dose Level 4

PTT-936 will be administered once a week (QW)

Group Type EXPERIMENTAL

PTT-936

Intervention Type DRUG

Eligible patients will receive single-agent PTT-936 administered per orally (PO).

PTT-936 Dose Level 5

PTT-936 will be administered once a week (QW)

Group Type EXPERIMENTAL

PTT-936

Intervention Type DRUG

Eligible patients will receive single-agent PTT-936 administered per orally (PO).

PTT-936 and anti-PD-1/L1 combination therapy

PTT-936 will be administered once a week (QW) in combination with a standard-of-care (SOC) regimen of an anti-PD-1/L1 agent every three weeks (Q3W)

Group Type EXPERIMENTAL

Combination of PTT-936 and anti-PD-1/L1 therapy

Intervention Type DRUG

Eligible patients will receive combination treatment consisting of PTT-936 administered PO in combination with a Standard of Care (SOC) regimen of an anti-PD-1/L1 agent administered intravenously (IV).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PTT-936

Eligible patients will receive single-agent PTT-936 administered per orally (PO).

Intervention Type DRUG

Combination of PTT-936 and anti-PD-1/L1 therapy

Eligible patients will receive combination treatment consisting of PTT-936 administered PO in combination with a Standard of Care (SOC) regimen of an anti-PD-1/L1 agent administered intravenously (IV).

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Voluntarily signed informed consent form (ICF).
2. Ability and willingness to adhere to all study procedures.
3. Male or female patients ≥ 18 years of age at the time of signing the ICF.
4. Locally advanced unresectable or metastatic solid tumor confirmed by histology or cytology
5. For Part A: On tumor imaging, as assessed by RECIST v1.1 and iRECIST, with measurable or unmeasurable disease. For Part B: On tumor imaging, as assessed by RECIST v1.1 and iRECIST, with at least one measurable disease.
6. Life expectancy ≥ 3 months.
7. Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0-1 for Part A and Part B.
8. Adequate end-organ and hematopoietic function, defined based on the following laboratory results obtained within 7 days prior to the first dose of study treatment \[Day 1\]):

1. Absolute neutrophil count (ANC) ≥ 1.5×109/L (1500/μL), without granulocyte colony-stimulating factor (G-CSF) support. Note that G-CSF may be administered until 14 days prior to Cycle 1 Day 1 (C1D1).
2. Platelet count ≥ 90×109/L (90,000/μL) without transfusion within 14 days prior to C1D1.
3. Hemoglobin ≥ 90 g/L (9 g/dL). Note that patients may be transfused or receive erythropoietic treatment to meet this criterion until 14 days prior to C1D1.
4. Creatinine clearance ≥ 60 mL/min.
5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x the upper limit of normal (ULN) with or without primary or metastatic liver tumor lesions.
6. Total bilirubin (TBIL) ≤ 1.5 x ULN.
7. For patients not receiving therapeutic anticoagulation: International Normalized Ratio (INR), activated partial thromboplastin time (aPTT) and prothrombin time (PT) ≤ 1.5 x ULN.
8. For patients receiving warfarin: INR ≤ 3.0 x ULN and no bleeding within 14 days prior to Day 1. Patients receiving therapeutic anticoagulation must be on a stable dose for a minimum of 14 days prior to Day 1. Patients on low molecular weight heparin will be allowed.

Exclusion Criteria

1. Patients with leptomeningeal (LMD) metastases or patients with new and/or progressive brain metastases at the time of study entry. Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after central nervous system (CNS)-directed treatment (radiotherapy and/or surgery), as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period.
2. History of primary malignancy other than the diseases under study, not in remission greater than three (3) years prior to Day 1. Exceptions that do not require a 3-year remission include: adequately treated non-melanoma skin cancer, cervical carcinoma in situ on biopsy or squamous intraepithelial lesion on Papanicolaou (PAP) smear, in situ prostate cancer (with no evidence of active disease for two \[2\] years prior to Day 1), or resected melanoma in situ and radically resected papillary thyroid carcinoma.
3. Persistence of Adverse Events (AEs) from prior anti-cancer therapy that have not resolved to Grade 1 (except for alopecia and hypothyroidism), or any history of Grade ≥ 3 immune-related adverse events (irAEs), Grade ≥ 2 pneumonitis, hypophysitis or encephalitis related to immunotherapy, or other Grade ≥ 3 drug-related CNS toxicity.
4. Active systemic autoimmune disease or a history of autoimmune disorder that may relapse (e.g., systemic lupus erythematosus \[SLE\], rheumatoid arthritis, inflammatory bowel disease \[IBD\], autoimmune thyroid disorder\*, multiple sclerosis, vasculitis, glomerulitis, eczema, psoriasis, etc.).

\*Note that primary or secondary hypothyroidism, well controlled with hormone replacement therapy is permitted.
5. Major trauma or major surgery within 4 weeks prior to Day 1 or anticipated major surgery during study participation.
6. Serious unhealing wound, ulcer, or bone fracture.
7. History of and/or presence of any of the following cardiovascular and cerebrovascular events or conditions:

1. History of myocardial infarction, unstable or severe angina, or arterial thrombotic event (such as cerebrovascular attack \[CVA\] or transient ischemic attack \[TIA\]) within 12 months prior to Day 1.
2. Significant abnormalities on the screening of ECG, including corrected QT interval (QTc interval) \> 470 msec (average of triplicate measurements, corrected for heart rate using Fridericia's formula), second degree (Mobitz type II) or third degree atrioventricular (AV) block, or other clinically significant (in the Investigator's opinion) arrhythmia.
3. Current New York Heart Association (NYHA) stage II-IV congestive heart failure (CHF).
4. Left ventricular ejection fraction (LVEF) \< 50%.

• Note that LVEF assessment by echocardiogram (ECHO) scan performed as part of the patient's regular care within 4 weeks prior to the screening visit may be used for confirmation of eligibility.
5. Other clinically significant (in the Investigator's opinion) cardiac diseases (e.g., valvular disease, cardiomegaly, ventricular hypertrophy, cardiomyopathy, myocarditis, etc.).
6. Uncontrolled hypertension (defined as a systolic blood pressure \[SBP\] ≥ 150 mmHg and/or diastolic blood pressure (DBP) ≥ 100 mmHg at screening), despite appropriate antihypertensive therapy, or poor compliance with an antihypertensive regimen.
8. Active or recent (past 6 months) bleeding disorder, including gastrointestinal (GI) bleeding, as evidenced by hematemesis, significant hemoptysis, or melena within 6 months prior to Day 1.
9. Uncontrolled diabetes.
10. Chronic severe liver disease or Child-Pugh B or C liver cirrhosis.
11. History of alcoholism or drug abuse within the past year.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No